Publication: Bevacizumab continuation beyond initial bevacizumab progression among recurrent glioblastoma patients
Issued Date
2012-10-23
Resource Type
ISSN
15321827
00070920
00070920
Other identifier(s)
2-s2.0-84867900118
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
British Journal of Cancer. Vol.107, No.9 (2012), 1481-1487
Suggested Citation
D. A. Reardon, J. E. Herndon, K. B. Peters, A. Desjardins, A. Coan, E. Lou, A. L. Sumrall, S. Turner, E. S. Lipp, S. Sathornsumetee, J. N. Rich, J. H. Sampson, A. H. Friedman, S. T. Boulton, D. D. Bigner, H. S. Friedman, J. J. Vredenburgh Bevacizumab continuation beyond initial bevacizumab progression among recurrent glioblastoma patients. British Journal of Cancer. Vol.107, No.9 (2012), 1481-1487. doi:10.1038/bjc.2012.415 Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/13588
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Bevacizumab continuation beyond initial bevacizumab progression among recurrent glioblastoma patients
Other Contributor(s)
Abstract
Background: Bevacizumab improves outcome for most recurrent glioblastoma patients, but the duration of benefit is limited and survival after initial bevacizumab progression is poor. We evaluated bevacizumab continuation beyond initial progression among recurrent glioblastoma patients as it is a common, yet unsupported practice in some countries. Methods: We analysed outcome among all patients (n99) who received subsequent therapy after progression on one of five consecutive, single-arm, phase II clinical trials evaluating bevacizumab regimens for recurrent glioblastoma. Of note, the five trials contained similar eligibility, treatment and assessment criteria, and achieved comparable outcome. Results: The median overall survival (OS) and OS at 6 months for patients who continued bevacizumab therapy (n55) were 5.9 months (95% confidence interval (CI): 4.4, 7.6) and 49.2% (95% CI: 35.2, 61.8), compared with 4.0 months (95% CI: 2.1, 5.4) and 29.5% (95% CI: 17.0, 43.2) for patients treated with a non-bevacizumab regimen (n44; P0.014). Bevacizumab continuation was an independent predictor of improved OS (hazard ratio0.64; P0.04). Conclusion: The results of our retrospective pooled analysis suggest that bevacizumab continuation beyond initial progression modestly improves survival compared with available non-bevacizumab therapy for recurrent glioblastoma patients require evaluation in an appropriately randomised, prospective trial. © 2012 Cancer Research UK All rights reserved.